Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Stroke. 1997;28:2031-2038

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oshiro, E. M.
Right arrow Articles by Tamargo, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oshiro, E. M.
Right arrow Articles by Tamargo, R. J.

(Stroke. 1997;28:2031-2038.)
© 1997 American Heart Association, Inc.

Articles

Inhibition of Experimental Vasospasm With Anti–Intercellular Adhesion Molecule-1 Monoclonal Antibody in Rats

Eric M. Oshiro, MD; Patricia A. Hoffman, MS; Gregory N. Dietsch, PhD; Mark C. Watts, MD; Drew M. Pardoll, MD, PhD; Rafael J. Tamargo, MD

From the Departments of Neurological Surgery (E.M.O., M.C.W., R.J.T.) and Molecular Biology and Genetics (D.M.P.) of the Johns Hopkins University School of Medicine, Baltimore, Md, and ICOS Corporation, Bothell, Wash (P.A.H., G.N.D.).

Correspondence to Rafael J. Tamargo, MD, Department of Neurological Surgery, The Johns Hopkins Hospital, Meyer 7-113, 600 N Wolfe St, Baltimore, MD 21287-7713.


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMaterials and Methods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Background and Purpose Inflammation may play a role in delayed chronic vasospasm after aneurysmal subarachnoid hemorrhage. We investigated the role of intercellular adhesion molecule-1 (ICAM-1) and macrophage/granulocyte infiltration in the rat femoral artery model of vasospasm using systemic administration of a murine anti–ICAM-1 monoclonal antibody (MAb).

Methods The femoral arteries (n=72) in Sprague-Dawley rats (n=36) were enclosed in latex pouches bilaterally. Autologous blood was injected into the pouch on one side, and saline was injected on the contralateral side. Chronic vessel narrowing was evaluated with the use of 29 rats, which were randomized into one of three groups for intraperitoneal injections: (1) anti–ICAM-1 MAb (2 mg/kg per dose, n=10), (2) isotype-matched MAb (2 mg/kg per dose, n=9), or (3) saline (n=10), given at 3 hours and 3, 6, and 9 days after blood exposure. These rats were killed 12 days after blood exposure, and femoral artery lumen cross-sectional areas were determined by computerized image analysis. Saturation of ICAM-1 binding sites with this dosing schedule was evaluated by fluorescence-activated cell sorter (FACS) analysis of splenocytes. Immunohistochemical studies with objective cell counts were performed to evaluate macrophage/granulocyte infiltration at 24 hours in 7 rats, comparing anti–ICAM-1 MAb treatment (n=4) with isotype-matched control MAb (n=3).

Results Animals treated with anti–ICAM-1 MAb showed a significant inhibition of arterial narrowing at 12 days (P=.0081), with lumen patency of 96.5±5.3% (mean±SEM), compared with 77.3±5.6% for isotype-matched MAb and 72.2±5.3% for saline-treated controls. FACS analysis of splenocytes from animals treated with anti–ICAM-1 MAb confirmed saturation of ICAM-1 binding sites. Vessels treated with anti–ICAM-1 MAb showed a significant decrease in inflammatory cell infiltrates, with objective macrophage/granulocyte counts of 31.3±26.6 (mean±SEM) per high-powered field, compared with 171.4±30.7 for isotype-matched control MAb (P=.0027).

Conclusions Anti–ICAM-1 MAb administered systemically starting 3 hours after blood exposure results in significant inhibition of chronic vasospasm in the rat femoral artery model and is correlated with a reduction in the number of infiltrating macrophages and granulocytes in the periadventitial region of blood-exposed arteries. We conclude that inflammatory changes associated with ICAM-1–mediated macrophage and granulocyte migration play an important role in the development of posthemorrhagic chronic vasospasm in this model.


Key Words: aneurysm • inflammation • subarachnoid hemorrhage • vasospasm • rats


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMaterials and Methods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
After an aneurysmal SAH, a major cause of cerebral ischemic injury and death is the delayed narrowing of the arterial vasculature, commonly referred to as chronic vasospasm. This delayed arteriopathy appears to be induced by the contact of blood with the adventitial surface of the vessel, but its etiology remains poorly understood. Based on several lines of indirect evidence, inflammation appears to play an important role in chronic vasospasm: (1) the presence of inflammatory cells coincident with chronic morphological changes in the walls of vasospastic vessels,1 2 3 4 5 (2) increased levels of immunoglobulins and complement components in serum and vessel walls during clinical vasospasm,5 6 7 8 9 10 and (3) the inhibition of experimental vasospasm with anti-inflammatory drugs11 12 and complement depletion.13

The recent characterization of three families of CAMs (immunoglobulin superfamily, integrins, and selectins) and the elucidation of their interactions during inflammation,14 allow for a renewed exploration of the inflammatory features of chronic vasospasm. CAMs are selectively expressed on cell membranes of endothelial cells and leukocytes and regulate the critical cellular interactions of the inflammatory response.15 ICAM-1, a member of the immunoglobulin superfamily of CAMs, is a transmembrane glycoprotein expressed on the surface of endothelial cells early in the response to local tissue injury.16 17 ICAM-1 mediates adhesion of macrophages, granulocytes, and eventually lymphocytes to endothelial cells by binding leukocyte-specific integrins (another subfamily of CAMs), namely, lymphocyte function-associated antigen-1 (LFA-1) and complement receptor 3 (CR3), also called Mac-1.18

We have previously shown that the expression of endothelial ICAM-1 increases 3 to 24 hours after the deposition of blood on the adventitial surface of arteries in the rat femoral artery model of vasospasm and that this increased expression correlates with the development of chronic vasospasm, which peaks 12 days after the hemorrhage.19 Animal studies by other groups have shown increased expression of ICAM-1 in the cerebral vasculature in response to ischemia20 and SAH.21 In humans, increased ICAM-1 expression in the brain has been documented in infarcts, viral encephalitis lesions, and multiple sclerosis plaques.22 Therefore, ICAM-1 appears to play a role in a wide range of CNS pathologies and may be similarly important in chronic vasospasm. In this study we demonstrate the specific inhibition of chronic vasospasm and ICAM-1–mediated endothelial cell-leukocyte interaction with the systemic administration of murine monoclonal antibodies against ICAM-1 in the rat femoral artery model of vasospasm.


*    Materials and Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Materials and Methods
down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Surgical Procedures
Blood exposure of rat femoral arteries was performed according to the method described by Okada and colleagues.23 Femoral arteries (n=72) were isolated by microsurgical dissection in the inguinal region of adult male Sprague-Dawley rats (n=36) weighing 200 to 250 g and anesthetized with an intraperitoneal injection (3 mL/kg) of a stock solution containing ketamine (25 mg/mL), xylazine (2.5 mg/mL), and ethyl alcohol (14.2%) in 0.9% NaCl. The isolated arteries were enclosed in an 8x8 mm latex pouch sealed loosely with cyanoacrylate glue. Autologous whole blood was harvested from the adjacent femoral vein, allowed to clot partially, and injected into the pouch. In the same animal, the contralateral femoral artery was prepared similarly, but normal saline was injected into the latex pouch, thus serving as an internal control (Fig 1Down). All animal procedures were performed in accordance with the institutional guidelines of the Johns Hopkins University School of Medicine Animal Care and Use Committee.



View larger version (95K):
[in this window]
[in a new window]
  		Figure 1. Surgical technique for the femoral artery model of vasospasm. An oblique incision is made in the inguinal region. A, The femoral artery is dissected free of the femoral vein and nerve. B, A latex pouch is placed around the artery. C, The pouch is sealed loosely with cyanoacrylate glue. D, Partially clotted autologous blood is injected into the pouch.

MAb Treatment
An anti-rat ICAM-1 MAb (27E4B, ICOS Corp) was generated by immunizing BALB/c mice three times at 21-day intervals with an activated rat T-cell line. Splenic lymphocytes from a single mouse were fused with NS-1 myeloma cells, and the resulting hybridomas were established and screened according to standard procedures. Supernatants were chosen for cloning based on their ability to block homotypic aggregation of concanavalin A–stimulated spleen cell blasts in response to PMA. An isotype-matched MAb (1B7.11, ATCC TIB 191, anti–2,4,6-trinitrophenyl) was used as a control.

Twenty-nine rats were used to evaluate the efficacy of anti–ICAM-1 MAb treatment for the inhibition of chronic vasospasm. These animals were randomized into three groups and received intraperitoneal injections of either anti–ICAM-1 MAb 27E4B (isotype IgG1, 2 mg/kg per dose, n=10), isotype-matched control MAb 1B7.11 (isotype IgG1, 2 mg/kg per dose, n=9), or saline solution (n=10) at 3 hours, 3 days, 6 days, and 9 days after surgery. The animals were killed 12 days after surgery, and the femoral arteries were harvested for routine histology and for measurement of lumen cross-sectional areas. This time point was chosen based on previous studies indicating that maximal vessel lumen narrowing occurs 12 days after blood exposure in this model.19

Seven rats were used for immunohistochemical studies to evaluate the infiltration of macrophages and granulocytes into the region of the blood-exposed femoral arteries 24 hours after surgery. The 24-hour time point has been previously shown to be within the window of increased ICAM-1 expression in this model.19 These animals received intraperitoneal injections of the anti–ICAM-1 MAb 27E4B (isotype IgG1, 2 mg/kg per dose, n=4) or the isotype-matched control MAb 1B7.11 (isotype IgG1, 2 mg/kg per dose, n=3) 3 hours after blood injection and were killed 24 hours after surgery. The femoral arteries were harvested for immunohistochemical staining for macrophages and granulocytes.

Blood Vessel Preparation
Femoral arteries were perfusion-fixed in situ with 4% paraformaldehyde in 0.1 mol/L PBS (pH 7.4) via cannulation of the aorta. The arteries were dissected out of the latex pouches and immersion-fixed in 4% paraformaldehyde for an additional 24 hours at 4°C. After fixation, the vessels were placed in 20% sucrose at 4°C for 24 hours for cryoprotection and frozen in tissue-embedding matrix by immersion in dry ice–equilibrated isopentane at -50°C. The embedded vessels were stored at -40°C until sectioning.

FACS Analysis for Determination of ICAM-1 Binding Site Saturation
Four rats from the efficacy experiment, 2 treated with the anti–ICAM-1 antibody and 2 with the isotype-matched control antibody, were used to evaluate saturation of ICAM-1 binding sites in treatment animals. Their spleens were harvested at the 12-day time point and minced in a sterile Petri dish with RPMI medium. The resulting splenocyte suspension was washed with RPMI and pelleted by centrifugation at 1500 rpm at 4°C. The pellet was then resuspended in ACK lysis buffer (0.15 mol/L NH4Cl, 1.0 mmol/L KHCO3, 0.1 mmol/L Na2EDTA, pH 7.4) and incubated at room temperature for 5 minutes to lyse red blood cells. The cells were washed three times with RPMI and resuspended in flow cytometry wash buffer (2% calf serum, 10 mmol/L HEPES, and 0.1% NaN3 in Hanks' balanced salt solution).

For each animal, two aliquots of 1x106 cells were pelleted by centrifugation at 1000 rpm for 5 minutes at 4°C. One of these aliquots from each animal was incubated with additional mouse anti–ICAM-1 antibody (1 µL, 3.2 mg/mL) for 20 minutes on ice to fully saturate ICAM-1 binding sites before FACS. Both aliquots of cells were then incubated with phycoerythrin-conjugated anti-mouse IgG for 20 minutes on ice. After incubation, the cells were washed and resuspended in 0.5 mL of wash buffer and run on FACScan (Becton Dickinson). ICAM-1 binding site saturation was determined by comparison of FACS histograms for cell samples with and without additional anti–ICAM-1 antibody.

Measurement of Blood Vessel Cross-Sectional Areas
The vessels were sectioned in a transverse orientation with the use of a cryostat (Microm) at a thickness of 10 µm and stained with hematoxylin and eosin. Lumen cross-sectional areas were determined by computerized image analysis on an Apple Macintosh 8100/80AV computer with the use of the public domain NIH Image program (developed at the US National Institutes of Health and available from the Internet by anonymous FTP from zippy.nimh.nih.gov). To correct for vessel deformation and off-transverse sectioning, the areas were determined by measuring the circumference of the vessel lumen and calculating the area as a generalized circle based on the measured circumference. For each vessel, five separate sections at least 200 µm apart were measured and averaged. For comparisons among treatment groups, the ratios of lumen cross-sectional areas of blood-exposed arteries to saline-exposed arteries in the same animal were calculated. Comparison of the group mean ratios was performed by the one-way ANOVA method (JMP-IN, SAS Institute).

Immunohistochemical Staining for Macrophages and Granulocytes
Immunohistochemical staining was used to evaluate the infiltration of macrophages and granulocytes into the blood-exposed and control femoral arteries. The femoral arteries were sectioned in a transverse orientation with the use of a cryostat (Microm) at a thickness of 10 µm, with at least 100 µm between sections. The slides were hydrated in PBS, then incubated in 3% normal horse serum for 20 minutes. The mouse OX-41 MAb (MAS 369, Harlan Sera-lab, Ltd) was diluted 1:200 in PBS with 1.0% bovine serum albumin and 3% normal horse serum, applied to each section, and incubated for 45 minutes in a humidified chamber. OX-41 detects a membrane antigen found on rat granulocytes and the majority of macrophages. It does not label lymphocytes or their precursors, mast cells, or platelets.24 25 After the slides were washed with PBS, they were incubated with biotinylated, horse anti-mouse IgG (rat absorbed, BA-2001, Vector Laboratories) diluted 1:100 in PBS with 1.0% bovine serum albumin and 3% normal horse serum for 45 minutes. The slides were washed in PBS, then incubated with avidin and biotinylated horseradish peroxidase macromolecular complex (Vectastain Elite, Vector Laboratories) for 30 minutes. The slides were washed in PBS and incubated for 8 minutes with peroxidase substrate (Vector VIP, Vector Laboratories). The slides were then washed in tap water, counterstained with nuclear fast red, and dry mounted.

A macrophage and granulocyte count was obtained by identifying all positive staining cells per representative high-powered field in a region adjacent to the adventitia of blood-exposed arteries. For each animal, three high-powered field sections of the blood-exposed artery were counted. Cell counts for anti–ICAM-1–treated and isotype-matched control arteries were compared with a two-group t test (JMP-IN, SAS Institute).


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMaterials and Methods
 *Results
down arrowDiscussion
 down arrowReferences
 
FACS Analysis for Determination of ICAM-1 Binding Site Saturation
To determine whether in vivo anti–ICAM-1 MAb injections were saturating all ICAM-1 sites, splenocytes from animals treated with anti–ICAM-1 MAb or control antibody were exposed to anti–ICAM-1 MAb in vitro followed by fluorescence-labeled secondary antibody. If all ICAM-1 sites were saturated by the in vivo anti–ICAM-1 treatment, then no additional staining should be seen when anti–ICAM-1 MAb is added in vitro.

FACS analysis performed on splenocytes from animals treated with 4 intraperitoneal doses of the anti–ICAM-1 MAb or control antibody (3 hours, 3 days, 6 days, and 9 days after blood exposure) revealed that ICAM-1 binding sites were saturated. Splenocytes harvested at day 12 from animals treated with the isotype-matched control antibody demonstrated a shift in the FACS histogram after addition of the anti–ICAM-1 MAb, indicating that ICAM-1 binding sites were not saturated in the control animals (Fig 2ADown). There was no shift in the FACS histogram from animals treated with the anti–ICAM-1 antibody when additional anti–ICAM-1 MAb was added to the cell preparation before FACScan (Fig 2BDown), confirming that ICAM-1 binding sites were saturated.



View larger version (18K):
[in this window]
[in a new window]
  		Figure 2. Representative histograms from FACS analysis for ICAM-1 binding site saturation. FACS histograms of splenocytes harvested from (A) control animals treated with isotype-matched nonspecific monoclonal antibodies and (B) anti–ICAM-1 treated animals. Splenocytes were stained with anti-mouse IgG alone (dotted lines) and with the addition of secondary anti–ICAM-1 MAb before anti-mouse IgG staining (solid lines). The absence of a shift in the FACS histogram for animals treated with anti–ICAM-1 MAb indicates that the ICAM-1 binding sites are saturated. This experiment was repeated twice with similar results. FL2-H indicates fluorescence intensity.

Vessel Lumen Narrowing From Blood Exposure
The mean ratios of blood-exposed to saline-exposed lumen cross-sectional area, expressed as percent lumen patency, were 96.5±5.3% (mean±SEM, n=10) for the animals treated with the anti–ICAM-1 MAb compared with 77.3±5.6% (n=9) for the animals treated with the isotype-matched control MAb and 72.2±5.3% (n=10) for saline control animals (Fig 3Down). This difference in lumen patency for the anti–ICAM-1 MAb treatment represents an 87.4% inhibition of vasospasm compared with control vessels and is statistically significant by one-way ANOVA (P=.0081).



View larger version (41K):
[in this window]
[in a new window]
  		Figure 3. Percent vessel lumen patency 12 days after blood exposure. Values represent mean ratios of lumen cross-sectional areas of blood-exposed to saline-exposed femoral arteries, expressed as percent lumen patency for saline-treated controls (n=10 animals), isotype-matched control MAb treatment (n=9 animals), and anti–ICAM-1 MAb treatment (n=10 animals). Note that the y-axis scale starts at 60% to emphasize the observed difference. Error bars represent SEM.

There was no significant systemic toxicity attributed to the 12-day anti–ICAM-1 MAb treatment. There was no apparent inhibition of surgical wound healing or increase in surgical wound infections in the animals that received the anti–ICAM-1 antibody. Histological examination of the blood vessels with hematoxylin and eosin staining did not reveal any deleterious effects of anti–ICAM-1 treatment compared with vessels of isotype-matched control antibody–treated and saline-treated control animals.

Immunohistochemical Staining for Macrophages and Granulocytes
Immunohistochemical staining for macrophages and granulocytes revealed a significant decrease in the inflammatory cell infiltrate in the region of the periadventitial blood clot in the animals treated with the anti–ICAM-1 MAb compared with that of control animals 24 hours after blood exposure (Fig 4Down). In animals treated with anti–ICAM-1 MAb, macrophage/granulocyte counts were 31.3±26.6 (mean±SEM, n=12 vessel sections) per high-powered field compared with 171.4±30.7 (n=9 vessel sections) per high-powered field for control animals (Fig 5Down). This decrease in the number of inflammatory cells for the animals treated with anti–ICAM-1 treated animals was statistically significant (P=.0027, two-group t test).



View larger version (75K):
[in this window]
[in a new window]
  		Figure 4. Representative photomicrographs of femoral artery sections stained for macrophages and granulocytes 24 hours after blood exposure. A, Isotype-matched control MAb–treated vessel shows a dense macrophage/granulocyte infiltrate encompassing the adventitia. B, Animal treated with anti–ICAM-1 MAb demonstrates a significant reduction in the inflammatory cell infiltrate in the periadventitial region of the blood-exposed vessel (OX-41 immunohistochemical stain with nuclear fast red counterstain, original magnification x200).



View larger version (38K):
[in this window]
[in a new window]
  		Figure 5. Mean macrophage/granulocyte counts per high-powered field (HPF) 24 hours after blood exposure. Immunohistochemical staining for macrophages and granulocytes was performed and positive staining cells per representative HPF were counted. Values represent means of objective cell counts for isotype-matched control MAb treatment (n=9 vessel sections) and anti–ICAM-1 MAb treatment (n=12 vessel sections). Error bars represent SEM.


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMaterials and Methods
 up arrowResults
 *Discussion
down arrowReferences
 
We previously reported the increased expression of endothelial ICAM-1 in response to the deposition of blood around arteries in the rat femoral artery model of vasospasm.19 In that study endothelial ICAM-1 expression increased 3 hours after blood deposition, remained elevated for 24 hours, and returned to baseline levels by 48 hours. The early increased expression of endothelial ICAM-1 was correlated with the development of chronic vasospasm 12 days after blood deposition.

In the present study the intraperitoneal administration of the anti–ICAM-1 MAb 27E4B, starting 3 hours after blood deposition and every 3 days subsequently, resulted in significant inhibition of chronic vasospasm at 12 days. FACS analysis of splenocytes from treated animals confirmed saturation of ICAM-1 binding sites with the dosing regimen used. Immunohistochemical studies demonstrated a significant decrease in the number of macrophages and granulocytes at 24 hours (toward the end of the window of increased endothelial ICAM-1 expression) in the periadventitial region of blood-exposed arteries treated with the anti–ICAM-1 MAb. These results suggest that after a perivascular hemorrhage, early ICAM-1–mediated interactions between endothelial cells and macrophages or granulocytes influence the development of chronic vasospasm 12 days later. Therefore, in this experimental model inflammation appears to play a major causative role in the development of chronic vasospasm.

Although the rat femoral artery is not a CNS vessel, it appears to respond to the adventitial blood-induced injury in a manner similar to that observed in human and primate intracranial vessels, particularly in the time course of delayed luminal narrowing and the histological appearance of the affected vessels. In humans and animals, prolonged exposure to blood after SAH results in two phases of lumen narrowing of the cerebral vessels, described as acute and chronic vasospasm.26 27 28 29 30 Acute or active vasospasm occurs hours after SAH, involves active vasoconstriction, and responds to papaverine. Chronic or passive vasospasm, by contrast, occurs roughly 1 week after SAH, involves passive vasoconstriction, and is insensitive to papaverine. We have identified these two phases in the femoral artery model of vasospasm, with significant peak lumen narrowing occurring between 1 and 12 hours and then again 12 days after the hemorrhage.19 The similarity in the time course of vessel narrowing suggests that the mechanism and pathophysiology of the blood injury in the rat femoral artery may be similar to that in human CNS vessels after SAH and that the findings in the femoral artery model of vasospasm can be cautiously generalized to the intracranial vasculature. Moreover, the histological changes associated with this vessel narrowing in the rat femoral artery model also closely parallel those seen in intracranial vessels in human SAH and animal models of SAH, most notably, thickening and corrugation of the internal elastic lamina, medial thickening, and infiltration of granulocytes and mononuclear cells.1 2 5 23

While cerebral arteries differ from systemic arteries in their endothelial permeability, response to vasoactive pharmacological agents, and components of the adventitial matrix, the similarities described above suggest an inflammatory mechanism that is preserved across both vessel types. Furthermore, the ICAM-1–mediated inflammatory mechanism that we consider here has been observed in intracranial arteries in response to both ischemic injury20 and SAH21 in animal models. These findings help validate the femoral artery model, as originally described by Okada and colleagues,23 as an appropriate system in which to study basic molecular mechanisms of inflammation in response to vessel or tissue injury that may be preserved across a wide variety of blood vessel types, such as the endothelial expression of ICAM-1. The morphological and physiological differences between peripheral and CNS arteries, or the concern that the degradation of blood peripherally differs significantly from its degradation in the subarachnoid space, should not invalidate the basic mechanisms of inflammation observed in this model.

Inflammation has long been suspected to play a role in chronic vasospasm. Aneurysmal SAH patients with severe chronic vasospasm have been shown to have significantly higher systemic temperatures than those of SAH patients without vasospasm.31 32 In vessels exposed to blood after SAH, Crompton1 identified collections of granulocytes and mononuclear leukocytes below the endothelial layer, and Hughes and Schianchi2 described numerous macrophages in the media and adventitia. These histological findings have also been observed in the primate SAH model.5 Several investigators have reported increased levels of immunoglobulins and complement fractions in the serum and vessel walls of patients in vasospasm,7 8 9 10 and one group has correlated these increased levels with poor outcome.9 Ibuprofen, a drug that not only disrupts prostaglandin synthesis but also specifically inhibits leukocyte-endothelial cell interactions,33 has been shown to prevent chronic vasospasm in dogs.11 12 These observations provide a body of evidence, though indirect, in favor of an inflammatory etiology in chronic vasospasm.

In the present study we demonstrate a primary role for ICAM-1 in the etiology of posthemorrhagic chronic vasospasm and directly implicate macrophages and granulocytes in this phenomenon. Handa and colleagues21 have shown an increased ICAM-1 expression in intracranial vessels in a rat model of SAH. Although the role of ICAM-1 in chronic vasospasm is only now becoming apparent, its role in cerebral ischemia is well documented. ICAM-1–mediated extravasation of leukocytes into ischemic cerebral tissue appears to potentiate the ischemic injury and may play an important role in the reperfusion injury of this tissue.20 34 35 Inhibition of leukocyte-endothelial cell binding using monoclonal antibodies against ICAM-1 results in a significant reduction of ischemic brain injury after temporary vascular occlusion.35 36 37 The potential applications of anti–ICAM-1 therapy in neurosurgical practice include cerebral protection during temporary clipping in aneurysm surgery, management of stroke, and the prevention of chronic vasospasm.

The role of ICAM-1, moreover, represents only one step for possible study in the pathway of endothelial cell–mediated migration of granulocytes (primarily neutrophils) and macrophages (derived from monocytes). The extravasation of leukocytes across the endothelial layer occurs in three distinct stages, with each stage involving a distinct set of CAMs.38 39 The first stage involves expression of selectins on the surface of activated endothelial cells within minutes to hours of injury and results in reversible binding of neutrophils and monocytes to the endothelium. We have focused on the second stage, which is mediated by ICAM-1 expressed on endothelial cells, because it results in irreversible binding of leukocytes that express the integrins LFA-1 and CR3 (Mac-1) to the endothelium. The third stage is mediated by cluster of differentiation 31 (CD31) and results in diapedesis and extravasation of these leukocytes across the endothelium.

The functions of these activated macrophages and neutrophils, however, may not be limited to phagocytosis. Leukocytes can induce inhibition of endothelial-dependent relaxation of the cerebral arteries by producing endothelins, which are powerful vasoconstrictors, and thus may directly affect vascular tone via mechanisms separate from their chronic inflammatory effect.40 In this way the inflammatory pathogenesis of chronic vasospasm can be reconciled with the currently favored hypothesis of nitric oxide/endothelin mediation of vasospasm.41 42 Endothelial cells regulate vascular tone by balancing the production of vasodilatory endothelium-derived relaxing factor, which has recently been identified as nitric oxide, and endothelins, a family of peptides that are potent vasoconstrictors. This endothelial-mediated balance of vascular tone can be disrupted by exogenous endothelin production from activated macrophages43 and neutrophils.44 Furthermore, activated neutrophils can directly inhibit endothelium-dependent relaxation,45 46 and activated macrophages can secrete toxic products implicated in chronic vasospasm, such as hydrogen peroxide, superoxide anion, hydroxyl radical, perhydroxyl radical, and singlet oxygen during enhanced phagocytosis.38 42 47

In summary, we describe the inhibition of posthemorrhagic chronic vasospasm in the rat femoral artery model using a murine anti–ICAM-1 MAb administered systemically starting 3 hours after the hemorrhage. We demonstrate a reduction in the number of infiltrating macrophages and granulocytes seen in the periadventitial region of blood-exposed arteries of animals treated with anti–ICAM-1 MAb. These results indicate that ICAM-1–mediated macrophage and granulocyte migration into the arterial wall may play a major role in the development of posthemorrhagic chronic vasospasm.


*    Selected Abbreviations and Acronyms
 
CAMs = cell adhesion molecules
CNS = central nervous system
FACS = fluorescence-activated cell sorter
ICAM-1 = intercellular adhesion molecule-1
MAb = monoclonal antibody
PBS = phosphate-buffered saline
PMA = phorbol 12-myristate 13-acetate
SAH = subarachnoid hemorrhage


*    Acknowledgments
 
This study was supported in part by the Richard S. Ross Clinician Scientist Award from the Johns Hopkins School of Medicine for the senior author (Dr Tamargo). The authors thank Dr George J. Dover, chairman of the Department of Pediatrics at the Johns Hopkins Hospital, for his guidance and Richard L. Jasman, BS, of ICOS Corporation for generation of the MAb.

Received May 5, 1997; revision received June 16, 1997; accepted June 25, 1997.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMaterials and Methods
 up arrowResults
 up arrowDiscussion
 *References
 

  1. Crompton MR. The pathogenesis of cerebral infarction following the rupture of cerebral berry aneurysms. Brain. 1964;87:491-510.[Free Full Text]
  2. Hughes JT, Schianchi PM. Cerebral artery spasm: a histological study at necropsy of the blood vessels in cases of subarachnoid hemorrhage. J Neurosurg. 1978;48:515-525.[Medline] [Order article via Infotrieve]
  3. Tanabe Y, Sakata K, Yamada Y. Cerebral vasospasm and ultrastructural changes in cerebral arterial wall. J Neurosurg. 1978;49:229-238.[Medline] [Order article via Infotrieve]
  4. Peterson JW, Kwun BD, Hackett JD, Zervas NT. The role of inflammation in experimental vasospasm. J Neurosurg. 1990;72:767-774.[Medline] [Order article via Infotrieve]
  5. Handa Y, Kabuto M, Kobayashi H, Kawano H, Takeuchi H, Hayashi M. The correlation between immunological reaction in the arterial wall and the time course of the development of cerebral vasospasm in a primate model. Neurosurgery. 1991;28:542-549.[Medline] [Order article via Infotrieve]
  6. Pellettieri L, Carlson CA, Lindholm L. Is the vasospasm following subarachnoidal hemorrhage an immunoreactive disease? Experientia. 1981;37:1170-1171.[Medline] [Order article via Infotrieve]
  7. Hoshi T, Shimizu T, Kito K, Yamasaki N, Takahashi K, Takahashi M, et al. Immunological study of late cerebral vasospasm in subarachnoid hemorrhage: detection of immunoglobulins, C3, and fibrinogen in cerebral arterial walls by immunofluorescence method [in Japanese]. Neurol Med Chir (Tokyo). 1984;24:647-654.[Medline] [Order article via Infotrieve]
  8. Pellettieri L, Nilsson B, Carlsson CA, Nilsson U. Serum immunocomplexes in patients with subarachnoid hemorrhage. Neurosurgery. 1986;19:767-771.[Medline] [Order article via Infotrieve]
  9. Ostergaard JR, Kristensen BO, Svehag SE, Teisner B, Miletic T. Immune complexes and complement activation following rupture of intracranial saccular aneurysms. J Neurosurg. 1987;66:891-897.[Medline] [Order article via Infotrieve]
  10. Kasuya H, Shimizu T. Activated complement components C3a and C4a in cerebrospinal fluid and plasma following subarachnoid hemorrhage. J Neurosurg. 1989;71:741-746.[Medline] [Order article via Infotrieve]
  11. Chyatte D, Rusch N, Sundt TM. Prevention of chronic experimental cerebral vasospasm with ibuprofen and high-dose methylprednisolone. J Neurosurg. 1983;59:925-932.[Medline] [Order article via Infotrieve]
  12. Chyatte D. Prevention of chronic vasospasm in dogs with ibuprofen and high-dose methylprednisolone. Stroke. 1989;20:1021-1026.[Abstract/Free Full Text]
  13. German JW, Gross CE, Giclas P, Watral W, Bednar MM. Systemic complement depletion inhibits experimental cerebral vasospasm. Neurosurgery. 1996;39:141-146.[Medline] [Order article via Infotrieve]
  14. Springer TA. Adhesion receptors of the immune system. Nature. 1990;346:425-434.[Medline] [Order article via Infotrieve]
  15. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol. 1993;11:767-804.[Medline] [Order article via Infotrieve]
  16. Simmons D, Makgoba MW, Seed B. ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM. Nature. 1988;331:624-626.[Medline] [Order article via Infotrieve]
  17. Staunton DE, Marlin SD, Stratowa C, Dustin ML, Springer TA. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell. 1988;52:925-933.[Medline] [Order article via Infotrieve]
  18. Larson RS, Springer TA. Structure and function of leukocyte integrins. Immunol Rev. 1990;114:181-217.[Medline] [Order article via Infotrieve]
  19. Sills AK, Clatterbuck RE, Thompson RC, Cohen PL, Tamargo RJ. Endothelial expression of intercellular adhesion molecule-1 (ICAM-1) in experimental vasospasm. Neurosurgery. 1997;41:453-461.[Medline] [Order article via Infotrieve]
  20. Okada Y, Copeland BR, Mori E, Tung MM, Thomas WS, del Zoppo GJ. P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke. 1994;25:202-211.[Abstract]
  21. Handa Y, Kubota T, Kaneko M, Tsuchida A, Kobayashi H, Kawano H, et al. Expression of intercellular adhesion molecule (ICAM-1) on the cerebral artery following subarachnoid hemorrhage in rats. Acta Neurochir (Wien). 1995;132:92-97.[Medline] [Order article via Infotrieve]
  22. Sobel R, Mitchell M, Fondren G. Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am J Pathol. 1990;136:1309-1316.[Abstract]
  23. Okada T, Harada T, Bark DH, Mayberg MR. A rat femoral artery model for vasospasm. Neurosurgery. 1990;27:349-356.[Medline] [Order article via Infotrieve]
  24. Robinson AP, White TM, Mason DW. Macrophage heterogeneity in the rats as delineated by two monoclonal antibodies MRC OX-41 and MRC OX-42, the latter recognizing complement receptor type 3. Immunology. 1986;57:239-247.[Medline] [Order article via Infotrieve]
  25. Noun A, Acker GM, Chaouat G, Antoine JC, Garabedian M. Cells bearing granulocyte-macrophage and T lymphocyte antigens in the rat uterus before and during ovum implantation. Clin Exp Immunol. 1989;78:494-498.[Medline] [Order article via Infotrieve]
  26. Taneda M, Otsuki H, Kumura E, Sakaguchi T. Angiographic demonstration of acute phase of intracranial arterial spasm following aneurysm rupture: case report. J Neurosurg. 1990;73:958-961.[Medline] [Order article via Infotrieve]
  27. Weir B, Grace M, Hansen J. Time course of vasospasm in man. J Neurosurg. 1978;48:173-178.[Medline] [Order article via Infotrieve]
  28. Vorkapic P, Bevan RD, Bevan JA. Longitudinal time course of reversible and irreversible components of chronic cerebrovasospasm of the rabbit basilar artery. J Neurosurg. 1991;74:951-955.[Medline] [Order article via Infotrieve]
  29. Harada T, Seto M, Sasaki Y, London S, Luo Z, Mayberg MR. The time course of myosin light chain phosphorylation in vasospasm. Neurosurgery. 1995;36:1178-1183.[Medline] [Order article via Infotrieve]
  30. MacDonald RL, Zhang J, Sima B, Johns L. Papaverine-sensitive vasospasm and arterial contractility and compliance after subarachnoid hemorrhage in dogs. Neurosurgery. 1995;37:962-968.[Medline] [Order article via Infotrieve]
  31. Rousseaux P, Scherpereel B, Bernard MH, Graftieaux JP, Guyot JF. Fever and cerebral vasospasm in ruptured intracranial aneurysms. Surg Neurol. 1980;14:459-465.[Medline] [Order article via Infotrieve]
  32. Weir B, Disney L, Grace M, Roberts P. Daily trends in white blood cell count and temperature after subarachnoid hemorrhage from aneurysm. Neurosurgery. 1989;25:161-165.[Medline] [Order article via Infotrieve]
  33. Nielsen VG, Webster RO. Inhibition of human polymorphonuclear leukocyte functions by ibuprofen. Immunopharmacology. 1987;13:61-71.[Medline] [Order article via Infotrieve]
  34. Connolly ES, Winfree CJ, Springer TA, Naka Y, Liao Y, Yan SD, et al. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion: role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest. 1996;97:209-216.[Medline] [Order article via Infotrieve]
  35. Zhang RL, Chopp M, Li Y, Zaloga C, Jiang M, Jones M, et al. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rat. Neurology. 1994;44:1747-1751.[Abstract/Free Full Text]
  36. Clark WM, Madden KP, Rothlein R, Zivin JA. Reduction of central nervous system ischemic injury by monoclonal antibody to intercellular adhesion molecule. J Neurosurg. 1991;75:623-627.[Medline] [Order article via Infotrieve]
  37. Zhang RL, Chopp M, Jiang N, Tang WX, Prostak J, Manning AM, et al. Anti–intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in Wistar rat. Stroke. 1995;26:1438-1443.[Abstract/Free Full Text]
  38. Janeway CA, Travers P. Immunobiology: The Immune System in Health and Disease. New York, NY: Current Biology Ltd/Garland Publishing, Inc; 1996.
  39. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301-314.[Medline] [Order article via Infotrieve]
  40. Faraci FM. Endothelium-derived vasoactive factors and regulation of the cerebral circulation. Neurosurgery. 1993;33:648-659.[Medline] [Order article via Infotrieve]
  41. Hino T, Tokuyama Y, Weir B, Takeda J, Yano H, Bell GI, et al. Changes in endothelial nitric oxide synthase mRNA during vasospasm after subarachnoid hemorrhage in monkeys. Neurosurgery. 1996;39:562-568.[Medline] [Order article via Infotrieve]
  42. Zabramski JM. Vasospasm after subarachnoid hemorrhage. In: Bederson JB, ed. Subarachnoid Hemorrhage: Pathophysiology and Management. Park Ridge, Ill: The American Association of Neurological Surgeons; 1997:127-156.
  43. Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med. 1990;172:1741-1748.[Abstract/Free Full Text]
  44. Sessa WC, Kaw S, Hecker M, Vane JR. The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochem Biophys Res Commun. 1991;174:613-618.[Medline] [Order article via Infotrieve]
  45. Akopov SE, Grigorian MR, Gabrielian ES. The endothelium-dependent relaxation of human middle cerebral arteries: effects of activated neutrophils. Experientia. 1992;48:34-36.[Medline] [Order article via Infotrieve]
  46. Csaki C, Szabo C, Benyo Z, Reivich M, Kovach AGB. Activated neutrophils inhibit cerebrovascular endothelium-dependent relaxations in vitro. Life Sci. 1991;49:1087-1094.[Medline] [Order article via Infotrieve]
  47. Nathan CF. Secretory products of macrophages. J Clin Invest. 1987;79:319-326.



This article has been cited by other articles:


Home page
 StrokeHome page
K. L. Chaichana, A. P. Levy, R. Miller-Lotan, S. Shakur, and R. J. Tamargo
Haptoglobin 2-2 Genotype Determines Chronic Vasospasm After Experimental Subarachnoid Hemorrhage
Stroke, December 1, 2007; 38(12): 3266 - 3271.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
R. L. Macdonald, Z.-D. Zhang, M. Takahashi, E. Nikitina, J. Young, A. Xie, and L. Larkin
Calcium sensitivity of vasospastic basilar artery after experimental subarachnoid hemorrhage
Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2329 - H2336.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
C J M Frijns, R Fijnheer, A Algra, J A van Mourik, J van Gijn, and G J E Rinkel
Early circulating levels of endothelial cell activation markers in aneurysmal subarachnoid haemorrhage: associations with cerebral ischaemic events and outcome
J. Neurol. Neurosurg. Psychiatry, January 1, 2006; 77(1): 77 - 83.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
H. Yatsushige, M. Yamaguchi, C. Zhou, J. W. Calvert, and J. H. Zhang
Role of c-Jun N-Terminal Kinase in Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage
Stroke, July 1, 2005; 36(7): 1538 - 1543.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
C.J.M. Frijns and L.J. Kappelle
Inflammatory Cell Adhesion Molecules in Ischemic Cerebrovascular Disease
Stroke, August 1, 2002; 33(8): 2115 - 2122.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
B. Noel, J. E. Conway, and R. J. Tamargo
Vascular Complications of Cocaine Use * Response
Stroke, July 1, 2002; 33(7): 1747 - 1748.
[Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
J J Nissen, D Mantle, B Gregson, and A D Mendelow
Serum concentration of adhesion molecules in patients with delayed ischaemic neurological deficit after aneurysmal subarachnoid haemorrhage: the immunoglobulin and selectin superfamilies
J. Neurol. Neurosurg. Psychiatry, September 1, 2001; 71(3): 329 - 333.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
Y. Aihara, H. Kasuya, H. Onda, T. Hori, J. Takeda, and F. M. Faraci
Quantitative Analysis of Gene Expressions Related to Inflammation in Canine Spastic Artery After Subarachnoid Hemorrhage Editorial Comment
Stroke, January 1, 2001; 32(1): 212 - 217.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
Q.-A. Thai, E. M. Oshiro, R. J. Tamargo, and J. P. Muizelaar
Inhibition of Experimental Vasospasm in Rats With the Periadventitial Administration of Ibuprofen Using Controlled-Release Polymers • Editorial Comment
Stroke, January 1, 1999; 30(1): 140 - 147.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oshiro, E. M.
Right arrow Articles by Tamargo, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oshiro, E. M.
Right arrow Articles by Tamargo, R. J.

Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.